MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Analysis of α-Synuclein Seed Amplification Assay in Carriers of GBA and LRRK2 Pathogenic Variants

    K. Fraser, A. Mirelman, O. Mabrouk, N. Omer, L. Concha-Marambio, T. Gurevich, A. Bar Shira, M. Gana-Weisz, O. Goldstein, A. Orr-Urtreger, M. Kestenbaum, J. Cedarbaum, T. Dam, J. Shirvan, N. Giladi, D. Graham, R. Alcalay, A. Thaler (Cambridge, USA)

    Objective: To assess α-synuclein seed amplification assay (αS-SAA) in cerebrospinal fluid (CSF) from a cohort of PD patients and non-manifesting carriers (NMCs) of pathogenic GBA…
  • 2023 International Congress

    Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson’s disease

    J. Szász, V. Constantin, K. Orban-Kiss, S. Bataga, L. Bancu, R. Neagoe, J. Szederjesi, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmari (TARGU MURES, Romania)

    Objective: To evaluate the profile of those patients with advanced Parkinson’s Disease (APD) in which we decided to use continuous 24-hour administration of Levodopa Carbidopa…
  • 2023 International Congress

    Ocular microtremor in Parkinson’s Disease: Protocol for an observational pilot study

    L. Graham, R. Morris, R. Vitorio, S. Stuart, A. Godfrey, R. Walker, C. Mcdonald (Newcastle, United Kingdom)

    Objective: This study aims to examine OMT in people with PD (PwPD) compared to healthy older adults. Identifying OMT as a PD biomarker could better…
  • 2023 International Congress

    NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.

    H. Berven, S. Kverneng, E. Sheard, M. Søgnen, S. Geijerstam, K. Haugarvoll, GO. Skeie, C. Dölle, C. Tzoulis (Bergen, Norway)

    Objective: To determine the safety of oral nicotinamide riboside (NR) 3000 mg daily for 4 weeks in Parkinson’s disease (PD). Secondary objectives: To assess NRs…
  • 2023 International Congress

    The spatial and spectral organization of thalamo-cortical connectivity in patients with essential tremor

    A. Steina, S. Schnitzler, J. Vesper, E. Florin, A. Schnitzler, J. Hirschmann (Düsseldorf, Germany)

    Objective: To identify cortical areas coupled to the ventral intermediate nucleus of the thalamus (VIM) in patients with essential tremor (ET). Background: ET is a…
  • 2023 International Congress

    Risk factors for Freezing of Gait in Parkinson’s Disease: A Systematic Review and Meta-analysis

    X. Zheng, J. Liu, S. Wang, R. Ou, C. Li, H. Shang (Chengdu, China)

    Objective: To comprehensively identify risk factors of freezing of gait (FOG) in Parkinson’s disease (PD), we performed a meta-analysis by combining the results of previous…
  • 2023 International Congress

    The association between compliance and the effects of home-based touchscreen training in Parkinson’s disease

    J. de Vleeschhauwer, E. Nackaerts, Y. Zhang, L. Janssens, W. Vandenberghe, A. Nieuwboer (Leuven, Belgium)

    Objective: To explore whether training success is determined by compliance as well as by cognitive function, depression and levodopa equivalent dosage (LEDD). Background: Training compliance…
  • 2023 International Congress

    Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease, in a movement disorder unit in Spain

    I. Muro Garcia, J. Alonso Maroto, B. Gonzalez Garcia, E. Carabajal Pendon, E. Casas, L. Lopez Manzanares (Madrid, Spain)

    Objective: To determine the number of patients that maintain infusion therapies (continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel (LCIG)) as treatment for advanced…
  • 2023 International Congress

    Understanding patient perceptions of advanced Parkinson’s disease (aPD) treatments

    J. Domingos, R. Pahwa, A. Antonini, I. Malaty, S. Lindvall, F. de Renzis, C. Yan, K. Pantiri, N. Touba, E. Evans, A. Alobaidi, A. Shewale, M. Shah, P. Kukreja, J. Zamudio, K. Chaudhuri (Orpington Kent, United Kingdom)

    Objective: To explore patients’ perceptions of treatment options for aPD and treatment decision considerations. Background: As PD advances, some people with Parkinson’s (PwP) on oral…
  • 2023 International Congress

    Vaccination from Covid-19 in people with Parkinson`s disease

    J. Salimjonov, N. Rashidova, K. Khalimova, R. Matmurodov (Tashkent, Uzbekistan)

    Objective: To assess safety and efficacy of COVID-19 vaccines against SARS-CoV-2 in people with Parkinson’s disease. Background: Different forms of vaccines have been developed to…
  • « Previous Page
  • 1
  • …
  • 113
  • 114
  • 115
  • 116
  • 117
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley